These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 29975796)

  • 1. Co-administration of proton pump inhibitors and/or of steroids may be a risk factor for low trough concentrations of posaconazole delayed-released tablets in adult patients with haematological malignancies.
    Cojutti PG; Candoni A; Lazzarotto D; Rabassi N; Fanin R; Hope W; Pea F
    Br J Clin Pharmacol; 2018 Nov; 84(11):2544-2550. PubMed ID: 29975796
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk factors for subtherapeutic levels of posaconazole tablet.
    Tang LA; Marini BL; Benitez L; Nagel JL; Miceli M; Berglund C; Perissinotti AJ
    J Antimicrob Chemother; 2017 Oct; 72(10):2902-2905. PubMed ID: 29091205
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment by Posaconazole Tablets, Compared to Posaconazole Suspension, Does Not Reduce Variability of Posaconazole Trough Concentrations.
    Gautier-Veyret E; Bolcato L; Roustit M; Weiss S; Tonini J; Brenier-Pinchart MP; Cornet M; Thiebaut-Bertrand A; Stanke-Labesque F
    Antimicrob Agents Chemother; 2019 Oct; 63(10):. PubMed ID: 31358587
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase 3 pharmacokinetics and safety study of a posaconazole tablet formulation in patients at risk for invasive fungal disease.
    Cornely OA; Duarte RF; Haider S; Chandrasekar P; Helfgott D; Jiménez JL; Candoni A; Raad I; Laverdiere M; Langston A; Kartsonis N; Van Iersel M; Connelly N; Waskin H
    J Antimicrob Chemother; 2016 Mar; 71(3):718-26. PubMed ID: 26612870
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy, safety and feasibility of antifungal prophylaxis with posaconazole tablet in paediatric patients after haematopoietic stem cell transplantation.
    Döring M; Cabanillas Stanchi KM; Queudeville M; Feucht J; Blaeschke F; Schlegel P; Feuchtinger T; Lang P; Müller I; Handgretinger R; Heinz WJ
    J Cancer Res Clin Oncol; 2017 Jul; 143(7):1281-1292. PubMed ID: 28258343
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety study and therapeutic drug monitoring of the oral tablet formulation of posaconazole in patients with haematological malignancies.
    Boglione-Kerrien C; Picard S; Tron C; Nimubona S; Gangneux JP; Lalanne S; Lemaitre F; Bellissant E; Verdier MC; Petitcollin A
    J Cancer Res Clin Oncol; 2018 Jan; 144(1):127-134. PubMed ID: 28932906
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population Pharmacokinetics of Posaconazole Tablets and Monte Carlo Simulations To Determine whether All Patients Should Receive the Same Dose.
    Petitcollin A; Boglione-Kerrien C; Tron C; Nimubona S; Lalanne S; Lemaitre F; Bellissant E; Verdier MC
    Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28848009
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevention of Invasive Aspergillus Fungal Infections with the Suspension and Delayed-Release Tablet Formulations of Posaconazole in Patients with Haematologic Malignancies.
    Leclerc E; Combarel D; Uzunov M; Leblond V; Funck-Brentano C; Zahr N
    Sci Rep; 2018 Jan; 8(1):1681. PubMed ID: 29374234
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fungal Prophylaxis with a Gastro-Resistant Posaconazole Tablet for Patients with Hematological Malignancies in the POSANANTES Study.
    Peterlin P; Chauvin C; Le Gouill S; Pere M; Dalichampt M; Guillaume T; Garnier A; Paré M; Le Bourgeois A; Moreau P; Chevallier P; Deslandes G; Gastinne T
    Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29133564
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Retrospective analysis of goal drug level attainment of posaconazole for invasive fungal infection prophylaxis in patients with acute myeloid leukemia pre- and post-switch to tablet formulation.
    Liebenstein TK; Widmer KM; Fallon MJ
    J Oncol Pharm Pract; 2018 Dec; 24(8):599-603. PubMed ID: 28768441
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Posaconazole liquid vs tablet formulation in lung transplant recipients.
    Stelzer D; Weber A; Ihle F; Matthes S; Ceelen F; Zimmermann G; Kneidinger N; Schramm R; Winter H; Zoller M; Vogeser M; Behr J; Neurohr C
    Mycoses; 2018 Mar; 61(3):186-194. PubMed ID: 29110351
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antifungal prophylaxis with posaconazole tablet and oral suspension in patients with haematologic malignancy: Therapeutic drug monitoring, efficacy and risk factors for the suboptimal level.
    Oh J; Kang CI; Kim SH; Huh K; Cho SY; Chung DR; Lee SY; Jung CW; Peck KR
    Mycoses; 2020 Jan; 63(1):89-94. PubMed ID: 31610064
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-Life Assessment of the Safety and Effectiveness of the New Tablet and Intravenous Formulations of Posaconazole in the Prophylaxis of Invasive Fungal Infections via Analysis of 343 Courses.
    Tverdek FP; Heo ST; Aitken SL; Granwehr B; Kontoyiannis DP
    Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28507111
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety, clinical effectiveness and trough plasma concentrations of intravenous posaconazole in patients with haematological malignancies and/or undergoing allogeneic haematopoietic stem cell transplantation: off-trial experience.
    Jeong W; Haywood P; Shanmuganathan N; Lindsay J; Urbancic K; Ananda-Rajah MR; Chen SC; Bajel A; Ritchie D; Grigg A; Seymour JF; Peleg AY; Kong DC; Slavin MA
    J Antimicrob Chemother; 2016 Dec; 71(12):3540-3547. PubMed ID: 27521358
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single-centre study of therapeutic drug monitoring of posaconazole in lung transplant recipients: factors affecting trough plasma concentrations.
    Jeong W; Snell GI; Levvey BJ; Westall GP; Morrissey CO; Wolfe R; Ivulich S; Neoh CF; Slavin MA; Kong DCM
    J Antimicrob Chemother; 2018 Mar; 73(3):748-756. PubMed ID: 29211913
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low dose posaconazole delayed release tablets for fungal prophylaxis in lung transplant recipients.
    Kozuch JM; Feist A; Yung G; Awdishu L; Hays S; Singer JP; Florez R
    Clin Transplant; 2018 Aug; 32(8):e13300. PubMed ID: 29806967
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Posaconazole therapeutic drug monitoring in clinical practice and longitudinal analysis of the effect of routine laboratory measurements on posaconazole concentrations.
    Märtson AG; Veringa A; van den Heuvel ER; Bakker M; Touw DJ; van der Werf TS; Span LFR; Alffenaar JC
    Mycoses; 2019 Aug; 62(8):698-705. PubMed ID: 31145490
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of posaconazole serum concentrations from haematological cancer patients on posaconazole tablet and oral suspension for treatment and prevention of invasive fungal infections.
    Pham AN; Bubalo JS; Lewis JS
    Mycoses; 2016 Apr; 59(4):226-233. PubMed ID: 26742659
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum posaconazole levels among haematological cancer patients taking extended release tablets is affected by body weight and diarrhoea: single centre retrospective analysis.
    Miceli MH; Perissinotti AJ; Kauffman CA; Couriel DR
    Mycoses; 2015 Jul; 58(7):432-6. PubMed ID: 26102575
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Utilization of posaconazole oral suspension or delayed-released tablet salvage treatment for invasive fungal infection.
    Kim JH; Benefield RJ; Ditolla K
    Mycoses; 2016 Nov; 59(11):726-733. PubMed ID: 27392814
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.